The company leverages innovative technologies including OncoSNIPER for therapeutic target selection using AI, Nanocyclix® for designing macrocyclic kinase inhibitors, and Promethe for developing radiolabeled molecules for radiotherapy. OPM-101 has advanced to Phase 1b/2a clinical trials (REVERT study) in advanced melanoma patients resistant to anti-PD-1 therapy.
Cyborg Score Rationale
The company achieved a 19% reduction in operating expenses and 21% improvement in operating income in 2024, demonstrating cost discipline. However, the termination of collaboration with Servier impacted 2025 budget significantly during a period of declining biotech investment, and current market capitalization stands at only $15.7M.
Top Insights
OPM-101 demonstrated positive Phase 1 results in October 2024, supporting advancement to patient studies
OPM reacquired OPM-201 (Parkinson's LRRK2 inhibitor) rights from Servier after completed Phase I safety trials, retaining full control of neurology asset
The company secured €5 million equity financing in April 2025 to strengthen cash position amid market uncertainty
OPM joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program, enhancing credibility in Parkinson's research
Named Competitors
Anti-PD-1 Checkpoint Inhibitors — Standard-of-care immunotherapy for resistant cancers with toxicity and resistance challenges